228 related articles for article (PubMed ID: 17404325)
1. Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade.
Liu L; Garcia AM; Santoro H; Zhang Y; McDonnell K; Dumont J; Bitonti A
J Immunol; 2007 Apr; 178(8):5390-8. PubMed ID: 17404325
[TBL] [Abstract][Full Text] [Related]
2. Exogenous IL-9 Ameliorates Experimental Autoimmune Myasthenia Gravis Symptoms in Rats.
Yao X; Zhao J; Kong Q; Xie X; Wang J; Sun B; Xu L; Mu L; Li H
Immunol Invest; 2018 Oct; 47(7):712-724. PubMed ID: 29944018
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis.
Gable KL; Guptill JT
Front Immunol; 2019; 10():3052. PubMed ID: 31998320
[TBL] [Abstract][Full Text] [Related]
4. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.
Duan RS; Adikari SB; Huang YM; Link H; Xiao BG
Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302
[TBL] [Abstract][Full Text] [Related]
5. Ocular myasthenia gravis induced by human acetylcholine receptor ϵ subunit immunization in HLA DR3 transgenic mice.
Wu X; Tuzun E; Saini SS; Wang J; Li J; Aguilera-Aguirre L; Huda R; Christadoss P
Immunol Lett; 2015 Dec; 168(2):306-12. PubMed ID: 26493475
[TBL] [Abstract][Full Text] [Related]
6. Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells.
Xu L; Villain M; Galin FS; Araga S; Blalock JE
Cell Immunol; 2001 Mar; 208(2):107-14. PubMed ID: 11333143
[TBL] [Abstract][Full Text] [Related]
7. Novel complement inhibitor limits severity of experimentally myasthenia gravis.
Soltys J; Kusner LL; Young A; Richmonds C; Hatala D; Gong B; Shanmugavel V; Kaminski HJ
Ann Neurol; 2009 Jan; 65(1):67-75. PubMed ID: 19194881
[TBL] [Abstract][Full Text] [Related]
8. Treatment of passively transferred experimental autoimmune myasthenia gravis using papain.
Poulas K; Tsouloufis T; Tzartos SJ
Clin Exp Immunol; 2000 May; 120(2):363-8. PubMed ID: 10792389
[TBL] [Abstract][Full Text] [Related]
9. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.
Smith B; Kiessling A; Lledo-Garcia R; Dixon KL; Christodoulou L; Catley MC; Atherfold P; D'Hooghe LE; Finney H; Greenslade K; Hailu H; Kevorkian L; Lightwood D; Meier C; Munro R; Qureshi O; Sarkar K; Shaw SP; Tewari R; Turner A; Tyson K; West S; Shaw S; Brennan FR
MAbs; 2018 Oct; 10(7):1111-1130. PubMed ID: 30130439
[TBL] [Abstract][Full Text] [Related]
10. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
Xiao BG; Duan RS; Zhu WH; Lu CZ
Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
[TBL] [Abstract][Full Text] [Related]
11. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
Ulusoy C; Çavuş F; Yılmaz V; Tüzün E
Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
[TBL] [Abstract][Full Text] [Related]
12. Specific removal of autoantibodies by extracorporeal immunoadsorption ameliorates experimental autoimmune myasthenia gravis.
Lazaridis K; Dalianoudis I; Baltatzidi V; Tzartos SJ
J Neuroimmunol; 2017 Nov; 312():24-30. PubMed ID: 28912035
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
[TBL] [Abstract][Full Text] [Related]
14. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
[TBL] [Abstract][Full Text] [Related]
15. Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention.
Patel DD; Bussel JB
J Allergy Clin Immunol; 2020 Sep; 146(3):467-478. PubMed ID: 32896307
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis.
Goluszko E; Deng C; Poussin MA; Christadoss P
J Neuroimmunol; 2002 Jan; 122(1-2):85-93. PubMed ID: 11777546
[TBL] [Abstract][Full Text] [Related]
17. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4.
Im SH; Barchan D; Maiti PK; Fuchs S; Souroujon MC
J Immunol; 2001 Jun; 166(11):6893-8. PubMed ID: 11359850
[TBL] [Abstract][Full Text] [Related]
18. [Modulation of experimental myasthenia gravis by IVIg].
Berrih-Aknin S; Aissaoui A; Yamamoto M; Kaveri SV
Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S25-9. PubMed ID: 10896985
[TBL] [Abstract][Full Text] [Related]
19. Fc-Receptor Targeted Therapies for the Treatment of
Keller CW; Pawlitzki M; Wiendl H; Lünemann JD
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071155
[No Abstract] [Full Text] [Related]
20. Dendritic cells exposed in vitro to TGF-beta1 ameliorate experimental autoimmune myasthenia gravis.
Yarilin D; Duan R; Huang YM; Xiao BG
Clin Exp Immunol; 2002 Feb; 127(2):214-9. PubMed ID: 11876742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
